MeSH D005910 - glioma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D018302:Neuroepithelial neoplasms
0 Companies
0 Drugs
Success rate
D005910:
Glioma
D000080443:Diffuse intrinsic pontine glioma
0 Companies
0 Drugs
Success rate
D001254:Astrocytoma
D004806:Ependymoma
D008527:Medulloblastoma
D009837:Oligodendroglioma
0 Companies
0 Drugs
Success rate
D018303:Ganglioglioma
0 Companies
0 Drugs
Success rate
D018316:Gliosarcoma
0 Companies
0 Drugs
Success rate
D020339:Optic nerve glioma
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Temozolomide | Temozolomide Teva | 2010-01-28 | |||
| Sandoz | Temozolomide | Temozolomide Sandoz | 2010-03-15 | |||
| Merck Sharp & Dohme | Temozolomide | Temodal | 1999-01-26 | |||
| Sun Pharmaceutical Industries | Temozolomide | Temozolomide Sun | 2011-07-13 | |||
| Accord Healthcare | Temozolomide | Temozolomide Accord | 2010-03-15 | |||
| Hexal | Temozolomide | Temozolomide Hexal | 2010-03-15 | |||
| medac | Temozolomide | Temomedac | 2010-01-25 |
Clinical Trials
Historical Success Rate
Phase 1
61%85/139
Phase 2
9%14/148
Phase 3
13%2/15
Approved: 1Overall Success rate: 1%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use